Stock Tickers: STEM, GERN, ASTM, VIAC, KOOL, CCELThere are some fresh developments that can affect the prices of stocks that would benefit from additional uses and additional applications for stem cell research, and these new developments may in fact lift certain cloning bans under some pre-set conditions. While these initiatives are overseas, they are un the UK and in Australia.Stem cell stocks up on lift of cloning ban in certain studies:Stemcells inc.-STEMGeron-GERN Aastrom Bio-ASTMViaCell-VIACThermogenics-KOOLCryo-Cell-CCELScientists in the United Kingdom have applied for a license to create hybrid embryos that use human cells and animal eggs for stem cell research. Some of the targeted areas will be to develop new treatments for Parkinson’s, stroke and Alzheimer’s. Kings College London and the North East England Stem Cell Institute (NESCI) submitted the application to the Human Fertilisation and Embryology Authority (HFEA), the regulatory body that regulates and supervises embryo research and fertility treatment. The proposed hybrid embryo will be 99.9 percent human and 0.1 percent animal, which may overcome a shortage of human eggs left over from IVF treatments, which have been used for stem cell research.Australia’s Prime Minister, John Howard, has allowed a vote on the controversial issue of lifting a cloning ban for stem celll research. The initial senate vote Tuesday a private members’ bill seeking to legalise therapeutic cloning won by 34 votes to 31 before the senate moved to discussion of proposed amendments. This would allow researchers to clone human embryos to extract their stem cells for disease treatment, although cloned embryos would have to be destroyed within 14 days and could not be implanted in a woman. Existing laws allow stem cells to be harvested only from surplus IVF embryos.Stem cell research has also, of course, been one of the issues in the U.S., and the elections today could be influential on the forward direction of stem cell research uses in the U.S. While that holds true in the US, cloning measures have raised far more controversy than stem cell research, so if you combine the two you will definitely be wanting a Congressional regime change today.
Stem Cell Research & Cloning Get Some Potential Fresh Air
Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.
McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.
His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.
A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.
TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.
McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.
Top Gaining Stocks
Top Losing Stocks